Future directions include designing a rigorous trial to examine the molecular and metabolic mechanisms by which SGLT2 inhibition mitigates the progression of DKD in T2D as well as determining whether the transcriptional changes observed in this study predict long-term progression of kidney injury and functional decline. The gene discussed is SLC5A2; the disease is diabetic kidney disease.